STOCKHOLM, June 13, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that the interim safety review of the clinical Phase 2a study EXIST showed exidavnemab to be safe and well-tolerated, whereby the second dose cohorts will now be initiated. The EXIST...
Hence then, the article about bioarctic to initiate next cohorts in exidavnemab phase 2a study after positive safety review was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( BioArctic to initiate next cohorts in exidavnemab Phase 2a study after positive safety review )
Also on site :
- No Doubt Guitarist Tom Dumont Reveals Early Onset Parkinson’s Disease Diagnosis
- Video: Severe flooding closes schools in Saudi Arabia
- ‘People are trying to be creative’: Tariff-battered American companies are so cash-starved they are using refund claims as collateral for loans